Is the business good?
How good a business is ZYME?
Zymeworks Inc. keeps −140% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−140%
Operating margin · Biotechnology median −72% · 12 months to Q1 2026
- Share count, year on year
- −0.71%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 167%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −481% |
| FY2021 | −808% |
| FY2022 | 32% |
| FY2023 | −182% |
| FY2024 | −180% |
| FY2025 | −87% |
Details›
- Operating margin12 months to Q1 2026
- −140%
- Net margin12 months to Q1 2026
- −126%
- Free cash flow margin
- −95%
- R&D as % of revenue
- 167%
- Revenue, trailing twelve months
- $81M
- Free cash flow, trailing twelve months
- −$77M
- Net income, trailing twelve months
- −$103M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.